This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Dec 15;11(24 Pt 1):8534-7.

doi: 10.1158/1078-0432.CCR-05-2250.

Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace?

Robert D Cardiff¹

Affiliations

Affiliation

¹ Center for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California, Davis School of Medicine, Davis, California 95616, USA. rdcardiff@ucdavis.edu

PMID: 16361534
DOI: 10.1158/1078-0432.CCR-05-2250

Comment

Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace?

Robert D Cardiff. Clin Cancer Res. 2005.

. 2005 Dec 15;11(24 Pt 1):8534-7.

doi: 10.1158/1078-0432.CCR-05-2250.

Author

Robert D Cardiff¹

Affiliation

¹ Center for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California, Davis School of Medicine, Davis, California 95616, USA. rdcardiff@ucdavis.edu

PMID: 16361534
DOI: 10.1158/1078-0432.CCR-05-2250

No abstract available

PubMed Disclaimer

Comment on

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC. Yauch RL, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98. doi: 10.1158/1078-0432.CCR-05-1492. Clin Cancer Res. 2005. PMID: 16361555

Similar articles

Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Laack E, Sauter G, Bokemeyer C. Laack E, et al. Lung Cancer. 2010 Sep;69(3):259-64. doi: 10.1016/j.lungcan.2010.05.015. Epub 2010 Jun 19. Lung Cancer. 2010. PMID: 20646778 Review.
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC. Rho JK, et al. Lung Cancer. 2009 Feb;63(2):219-26. doi: 10.1016/j.lungcan.2008.05.017. Epub 2008 Jul 2. Lung Cancer. 2009. PMID: 18599154
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC. Yauch RL, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98. doi: 10.1158/1078-0432.CCR-05-1492. Clin Cancer Res. 2005. PMID: 16361555
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD. Thomson S, et al. Cancer Res. 2005 Oct 15;65(20):9455-62. doi: 10.1158/0008-5472.CAN-05-1058. Cancer Res. 2005. PMID: 16230409
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL. Comis RL. Oncologist. 2005 Aug;10(7):467-70. doi: 10.1634/theoncologist.10-7-467. Oncologist. 2005. PMID: 16079313 Review. No abstract available.

See all similar articles

Cited by

G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer.
Jin Y, Park S, Park SY, Lee CY, Eum DY, Shim JW, Choi SH, Choi YJ, Park SJ, Heo K. Jin Y, et al. Int J Mol Sci. 2022 Jan 6;23(2):589. doi: 10.3390/ijms23020589. Int J Mol Sci. 2022. PMID: 35054776 Free PMC article.
Immunohistochemical Expression of the Epithelial to Mesenchymal Transition Proteins E-cadherin and ß-catenin in Grades of Oral Squamous Cell Carcinoma.
Kumar V, Panda A, Dash KC, Bhuyan L, Mahapatra N, Mishra P. Kumar V, et al. J Pharm Bioallied Sci. 2021 Jun;13(Suppl 1):S555-S560. doi: 10.4103/jpbs.JPBS_562_20. Epub 2021 Jun 5. J Pharm Bioallied Sci. 2021. PMID: 34447152 Free PMC article.
Extracellular Vesicle Transfer from Endothelial Cells Drives VE-Cadherin Expression in Breast Cancer Cells, Thereby Causing Heterotypic Cell Contacts.
Rezaei M, Martins Cavaco AC, Stehling M, Nottebaum A, Brockhaus K, Caliandro MF, Schelhaas S, Schmalbein F, Vestweber D, Eble JA. Rezaei M, et al. Cancers (Basel). 2020 Aug 1;12(8):2138. doi: 10.3390/cancers12082138. Cancers (Basel). 2020. PMID: 32752204 Free PMC article.
LZAP promotes the proliferation and invasiveness of cervical carcinoma cells by targeting AKT and EMT.
Dai YF, Lin N, He DQ, Xu M, Zhong LY, He SQ, Guo DH, Li Y, Huang HL, Zheng XQ, Xu LP. Dai YF, et al. J Cancer. 2020 Jan 14;11(6):1625-1633. doi: 10.7150/jca.39359. eCollection 2020. J Cancer. 2020. PMID: 32047568 Free PMC article.
Circular RNAs: epigenetic regulators in cancerous and noncancerous skin diseases.
Abi A, Farahani N, Molavi G, Gheibi Hayat SM. Abi A, et al. Cancer Gene Ther. 2020 May;27(5):280-293. doi: 10.1038/s41417-019-0130-x. Epub 2019 Sep 3. Cancer Gene Ther. 2020. PMID: 31477805 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

-